BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes

https://doi.org/10.1016/0014-2999(94)00485-4Get rights and content

Abstract

The effects of BAY u9773 (6(R)-(4′-carboxyphenylthio)-5(S)-hydroxy-7(E),9(E),11(Z),14(Z)-eicosatetraenoic acid), a cysteinyl- leukotriene analogue, were investigated on a variety of smooth muscle preparations in order to determine its profile as a cysteinyl-leukotriene receptor antagonist. The tissues were contracted with leukotriene C4 or leukotriene D4 and their receptor characteristics defined as either ‘typical’ or ‘atypical’ accordingto the activity or inactivity, respectively, of the selective antagonists ICI 198615, MK 571 and SKF 104353. BAY u9773 antagonised ‘typical’ cysteinyl-leukotriene receptors with pA2 (or pKB) values in the range 6.8–7.4 and also antagonised ‘atypical’ receptors with pA2 values in the range 6.8–7.7. However, BAY u9773 had no effect at 10−6 M against a selection of non-leukotriene stimuli in the same preparations. BAY u9773 competitively displaced [3H]leukotriene D4 binding to guinea-pig lung homogenate, with a pKi of 7.0 ± 0.1. In the guinea-pig lung strip, BAY u9773 was found to be inactive at 10−6 M against leukotriene C4- and leukotriene D4-induced contractions, which may suggest the existence of a third type of cysteinyl-leukotriene receptor. These data demonstrate that BAY u9773 is a selective cysteinyl-leukotriene receptor antagonist with comparable activity at both ‘typical’ and ‘atypical’ receptors and as such represents a valuable tool for the study of cysteinyl-leukotriene receptors.

References (26)

  • W.W. Busse et al.

    The role of leukotriene antagonists and inhibitors in the treatment of airway disease

    Am. Rev. Resp. Dis.

    (1991)
  • Y.C. Cheng et al.

    Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction

    Biochem. Pharmacol.

    (1973)
  • J.W. Constantine

    The spirally cut tracheal strip preparation

    J. Pharm. Pharmacol.

    (1965)
  • Cited by (74)

    • Potential role of leukotriene receptor antagonists in reducing cardiovascular and cerbrovascular risk: A systematic review of human clinical trials and in vivo animal studies

      2018, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      CysLT1R and CysLT2R are the two G-protein coupled receptors of the CysLTs [3] that are found in injured human arteries [4,5]. Montelukast, zafirlukast, pranlukast and pobilukast were the first leukotriene receptor antagonists (LTRA) and selective inhibitors of CysLT1 receptor that were approved for use in asthmatic patients [6,7], and later on for the treatment of allergic rhinitis and urticaria [8]. In experimental models (in vivo), they have demonstrated to play a role in reducing the blood-brain barrier permeability and brain injuries [9–12].

    • Leukotriene C<inf>4</inf> induces bronchoconstriction and airway vascular hyperpermeability via the cysteinyl leukotriene receptor 2 in S-hexyl glutathione-treated guinea pigs

      2015, European Journal of Pharmacology
      Citation Excerpt :

      As LTD4 is known to activate both human CysLT1 and CysLT2 receptors, it would be interesting to see if both CysLT1 and CysLT2 receptors are involved in human bronchoconstriction. It has been shown that a CysLT1 receptor antagonist does not completely inhibit tracheal contraction induced by high concentrations of LTD4 and that residual contraction to LTD4 is inhibited by the CysLT1/LT2 receptor antagonist BAY u9773 (Bäck et al., 2001; Tudhope et al., 1994). In addition to bronchoconstriction, CysLTs also induce potent airway vascular hyperpermeability (Nakagawa et al., 1992).

    • The role of leukotrienes in allergic diseases

      2015, Allergology International
      Citation Excerpt :

      CysLT1 is sensitive to classical antagonists such as montelukast, zafirlukast, pranlukast, pobilukast, and MK571, whereas CysLT2 mediates several effects that are not inhibited by classical antagonists.129 One compound, BAYu9773, antagonizes both CysLT1 and CysLT2 receptors; however, it is neither potent nor selective for these CysLT receptors, especially in human tissues.130 A recent report suggests that BAYu9773 partially agonizes CysLT2.131

    View all citing articles on Scopus
    View full text